Navigation Links
Medicare Announces Expanded Coverage for Warfarin Patients Monitoring Clotting Time at Home
Date:3/19/2008

Decision makes convenient self-testing a financial reality for more

anticoagulation patients

INDIANAPOLIS, March 19 /PRNewswire/ -- Medicare Part B will now cover and pay for meter training, equipment and supplies for all long-term warfarin users who monitor their prothrombin time at home with a portable handheld meter. The change opens the door to greater convenience and potentially fewer complications for a broader spectrum of anticoagulation patients.

Medicare previously reimbursed these expenses only for patient self- testers who had mechanical heart valves. The new coverage expands to include those on anticoagulant medication with chronic atrial fibrillation and venous thromboembolism.

"This expanded coverage will give more warfarin patients the flexibility to test when and where they want," said Dr. Alan Jacobson, cardiologist, Loma Linda University School of Medicine. "Now, patients who travel extensively or who have difficulty with access to their doctor's office or a centralized location can monitor their INR at home. If they test more often, it's easier to manage their therapy and keep their medication in the therapeutic range."

Some patients travel to their doctor's office or an anti-coagulation clinic as often as once a week to make sure their warfarin is appropriately regulated. While warfarin is commonly prescribed to prevent thrombosis, or blood clots, it must also be carefully monitored to prevent bleeding.

Portable, handheld prothombin time (PT/INR) meters, like the CoaguChek(R) XS System for Patient Self-Testing, enable patients to test their clotting time at home in about a minute, using a small drop of blood from a simple fingerstick. Currently, in the United States, less than 5 percent of patients on blood thinners perform self-testing, according to the Centers for Medicare and Medicaid Services.

Studies suggest that anticoagulation patients who self-test may experience fewer complications overall than those who do not, because self-testing may increase patient time in therapeutic range.(1) Studies also suggest that PT/INR self-testing (performed with a blood sample from a fingerstick) is just as accurate as fingerstick testing performed by a healthcare professional and conventional testing performed on a laboratory analyzer.(2,3,4)

"I feel comfortable with more of my patients monitoring from home because handheld meters like the CoaguChek XS System are easy to use, and I know the results will be as reliable as results from our office meter and from the lab," said Dr. Jacobson. "Plus, this gives my patients the convenience of testing at home with a simple fingerstick rather than having blood drawn from their arm and waiting for lab results."

Under the new Medicare B policy, the patient portion of costs for self- testing is expected to be about $30 a month (based on a national average) for the use of a PT/INR meter and test strips, and about $35 for the initial training. Patients with supplemental insurance coverage could potentially have little or no out-of-pocket expenses.

All patients on anticoagulant medication need a prescription from their doctor for a self-testing meter and supplies before being able to monitor their own clotting time at home. Patient self-testing is also designed to augment, not eliminate, testing and therapy management that is overseen by a doctor. Patients who self-test notify their doctors of clotting time results so they can make the proper adjustments to medication.

Patients interested in finding out more about self-testing their PT/INR should talk to their doctor. For more information on the CoaguChek XS System for Patient Self-Testing, visit http://www.ASmartWayToTest.com.

About Anticoagulation Monitoring

Certain patients with atrial fibrillation, a mechanical heart valve or deep vein thrombosis require protection against thrombosis, or blood clots. They are typically put on lifelong oral anticoagulation therapy with warfarin sodium (e.g., Coumadin) to thin their blood. Each patient reacts differently to anticoagulant medications, so it is imperative to monitor therapeutic effects closely to minimize potential risks.

About CoaguChek products

Physicians have been using CoaguChek instruments for point-of-care PT/INR testing since 1994. Today, in the U.S., more point-of-care PT/INR tests are performed with a CoaguChek system than with all other devices combined.(5) The CoaguChek XS System represents the fifth generation of point-of-care anticoagulation monitoring devices from Roche Diagnostics.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007, sales by the Pharmaceuticals Division totalled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested more than 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people. Additional information is available on the Internet at http://www.roche.com.

References

(1) Kortke H, Minami K, Breymann T, et al. INR self-management after

mechanical heart valve replacement: ESCAT. Z Kardiol. 2001;90 (6)118-

124.

(2) CoaguChek XS system package insert. Indianapolis, IN. Roche

Diagnostics Corporation; 2006.

(3) Bussey HI, Chiquette E, Bianco TM, et al. A statistical and clinical

evaluation of fingerstick and routine laboratory prothrombin time

measurements. Pharmacotherapy. 1997;17(5): 861-866.

(4) Kaatz SS, White RH, Hill J, et al. Accuracy of laboratory and portable

monitor international normalized ratio determinations. Comparison with

a criterion standard. Arch Intern Med. 1995;155:1861-1867.

(5) Second Quarter 2007 total market share of projected distributor unit

sales of the Point of Care Testing Coagulation Reagents and Kits

product class by HPIS Market Intelligence, a division of GHX Global

Healthcare Exchange.

All trademarks used or mentioned in this release are legally protected by law.

For further information, please contact:

Media: Healthcare Professionals and Patients:

Lori McLaughlin

Corporate Communications

Roche Diagnostics Corporation,

Indianapolis, Ind.

Phone: 317-521-3112 Phone : 1-800-852-8766

lori.mclaughlin@roche.com Option 2 for Healthcare Professionals

and Option 4 for Patients


'/>"/>
SOURCE Roche Diagnostics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
2. Lack of Medicare Part D Coverage for All Medically Necessary Prescriptions Endangers Older Americans and Those with Chronic Diseases and Disabilities
3. Oncologists Call For Medicare to Reconsider Anemia Drug Restrictions
4. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
5. Local Medicare Contractors Expand Hypertension Coverage for CardioDynamics BioZ(R) ICG Technology
6. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
7. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
11. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... WASHINGTON , May 26, 2016 ... Microspheres, Associated With Both Cost Savings and ... BTG plc (LSE: BTG), an international specialist healthcare ... data at the 21st Annual Meeting of ISPOR ... that treatment of hepatocellular carcinoma (HCC) using yttrium-90 ...
(Date:5/25/2016)... und GERMANTOWN, Maryland , May ... mit Therawis bedient dringenden ... QIAGEN N.V. (NASDAQ: QGEN ... eine Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH ... Onkologie eingegangen zu sein. Ein erstes Projekt wird ...
(Date:5/25/2016)... 2016 As illustrated by the ... month, the numbers and momentum of cannabis in the ... the billions, more research and development push the sector ... of Legal Marijuana Markets Report  from from ArcView Market ... of the increase in sector is attributed to adult ...
Breaking Medicine Technology:
(Date:5/26/2016)... , ... May 26, 2016 , ... ... Degeneration” for the Foundation Fighting Blindness, Long Island Chapter on June 4, 2016, ... public. , Dr. Maisel, founder of Retina Group of New York , ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... In an effort to provide hair restoration ... to both Snapchat users and those who do not use the app. Dr. Mohebi, the ... new page, Dr. Mohebi Live . , Dr. Mohebi says, “The positive response ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership ... solutions, today announced the organization has earned its ISO 13485 certification, indicating the ... compliant with all rules and policies associated with ISO quality standard 13485. ...
(Date:5/26/2016)... ... ... The Lung Institute has partnered with the Gulfcoast North Area ... at their clinic in downtown Tampa. The class is complimentary for the public. Register ... a free downloadable 4 Week Smoking Cessation Guide for those who are ...
(Date:5/26/2016)... ... May 26, 2016 , ... Nike Yoga Camps ... from daily practices, arts & crafts, discussions, and games all geared towards enhancing ... Evans have combined backgrounds in kids’ yoga, collegiate sport yoga instruction, and global ...
Breaking Medicine News(10 mins):